Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
Weight Loss and Sleep-Disordered Breathing
A 2026 review explains how weight management, tirzepatide and positive airway pressure fit into care for obesity-related sleep breathing disorders.
Semaglutide and Ischemic Colitis
A 2026 oral semaglutide case report describes ischemic colitis recurring after rechallenge, a stronger signal that still cannot prove general risk.
How drug promotion shapes prescribing
A 2026 Cochrane review links pharmaceutical promotion with prescribing quality, quantity, and cost, with important limits on causality.
Semaglutide plus dapagliflozin in CKD
A short retrospective study compared semaglutide, dapagliflozin, and their combination in type 2 diabetes with chronic kidney disease.
BPC-157 and TB-500 for tendon tears
Why an online BPC-157 or TB-500 protocol cannot establish tendon healing when controlled human evidence and safety data are missing.
HD1916 trial: chemically made semaglutide
A Phase III trial found HD1916 met its prespecified equivalence criterion against reference semaglutide for weight change at 44 weeks.
Multi-peptide stack safety: evidence limits
A forum list of peptide products cannot establish product quality, compatibility, or personal safety. Here is what an evidence-aware review requires.
Semaglutide care and weight-loss pressure
How to separate online weight-loss pressure from evidence, product labels, and an individualized conversation with a semaglutide prescriber.
Semaglutide constipation: safety boundaries
What current Wegovy labelling and trial evidence can say about constipation, plus the urgent-care boundary for serious digestive symptoms.
Buying Semaglutide Online: What to Verify
A source-based checklist for checking semaglutide telehealth marketing, compounded-drug status, FDA-approved labels, and pharmacy details.
Tirzepatide and kidney outcomes
A 2026 cohort study compared GLP-1/GIP therapies, including tirzepatide, with finerenone in type 2 diabetes and chronic kidney disease.
Tirzepatide and oral symptoms
A 2026 paper describes reported oral and salivary symptoms with incretin medicines, but it does not establish causation for tirzepatide.